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Abstract
Introduction The potential of applying data analysis tools to
microarray data for diagnosis and prognosis is illustrated on the
recent breast cancer dataset of van 't Veer and coworkers. We
re-examine that dataset using the novel technique of logical
analysis of data (LAD), with the double objective of discovering
patterns characteristic for cases with good or poor outcome,
using them for accurate and justifiable predictions; and deriving
novel information about the role of genes, the existence of
special classes of cases, and other factors.
Method Data were analyzed using the combinatorics and
optimization-based method of LAD, recently shown to provide
highly accurate diagnostic and prognostic systems in
cardiology, cancer proteomics, hematology, pulmonology, and
other disciplines.
Results LAD identified a subset of 17 of the 25,000 genes,
capable of fully distinguishing between patients with poor,
respectively good prognoses. An extensive list of 'patterns' or
'combinatorial biomarkers' (that is, combinations of genes and
limitations on their expression levels) was generated, and 40
patterns were used to create a prognostic system, shown to
have 100% and 92.9% weighted accuracy on the training and
test sets, respectively. The prognostic system uses fewer genes
than other methods, and has similar or better accuracy than
those reported in other studies. Out of the 17 genes identified
by LAD, three (respectively, five) were shown to play a
significant role in determining poor (respectively, good)
prognosis. Two new classes of patients (described by similar
sets of covering patterns, gene expression ranges, and clinical
features) were discovered. As a by-product of the study, it is
shown that the training and the test sets of van 't Veer have
differing characteristics.
Conclusion The study shows that LAD provides an accurate
and fully explanatory prognostic system for breast cancer using
genomic data (that is, a system that, in addition to predicting
good or poor prognosis, provides an individualized explanation
of the reasons for that prognosis for each patient). Moreover, the
LAD model provides valuable insights into the roles of individual
and combinatorial biomarkers, allows the discovery of new
classes of patients, and generates a vast library of biomedical
research hypotheses.
Introduction
Microarray gene expression technology has provided exten-
sive datasets that describe patients with cancer in a new way.
Several methodologies have been used to extract information
from these datasets. In this study we used the methodology of
logical analysis of data (LAD) [1,2] to reanalyze the publicly
available microarray dataset reported by van 't Veer and cow-
orkers [3]. The motivation for using yet another method to ana-
lyze these data was the expectation that the specific aspects
of LAD, and especially the combinatorial nature of its
LAD = logical analysis of data.Breast Cancer Research    Vol 8 No 4    Alexe et al.
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approach, would allow the extraction of new information on the
problem of metastasis-free survival of breast cancer patients,
and in particular on the role of various significant combinations
of genes that may have an influence on this outcome.
The main goal of the study by van 't Veer and coworkers was
to predict the clinical outcome of breast cancer (that is, to
identify those patients who will develop metastases within 5
years) based on analysis of gene expression signatures. The
crucial importance of this problem arises from the fact that the
available adjuvant (chemo or hormone) therapy, which
reduces by about one-third the risk for distant metastases, is
not really necessary for 70–80% of the patients who currently
receive it. Moreover, this therapy can have serious side effects
and involves high medical costs. The study by van 't Veer and
coworkers illustrates clearly that machine learning techniques,
data mining, and other new techniques applied to DNA micro-
array analysis can outperform most clinical predictors currently
in use for breast cancer. The study concludes that the new
findings, '... provide a strategy to select patients who would
benefit from adjuvant therapy'.
A specific feature of datasets coming from genomics is the
presence of a very large number of measurements concerning
gene expressions but only a relatively small number of obser-
vations. For instance, the attributes in the van 't Veer study cor-
respond to more than 25,000 human genes, whereas the
number of cases was only 97. In that dataset, each case is
described by the expression levels of 25,000 genes, as meas-
ured by fluorescence intensities of RNA hybridized to microar-
rays of oligonucleotides. The cases included in the dataset are
97 lymph-node-negative breast cancer patients, who are
grouped into a training set of 78 and a test set of 19 cases.
The training set includes 34 positive cases (having a 'poor
prognosis' signature; that is, having fewer than 5 years of
metastasis-free survival) and 44 negative cases (having a
'good prognosis' signature; i.e. having more than 5 years of
metastasis-free survival). The test set includes 12 positive and
seven negative cases.
The van 't Veer study used DNA microarray analysis in primary
breast tumors, and "applied supervised classification to iden-
tify gene expression signature strongly predictive of a short
interval to distant metastases ('poor prognosis' signature) in
patients without tumor cells in local lymph nodes at diagnosis
(lymph node negative)". The study identified 231 genes as
being significant markers of metastases, all of whose correla-
tions with outcome exceeded 0.3 in absolute value, and it con-
structed an optimal prognosis classifier based on the best 70
genes. In the training set the system predicted correctly the
class of 65 of the 78 cases (that is, with an accuracy of 83.3%,
corresponding to a weighted accuracy of 83.6%), whereas in
the test set it predicted correctly the class of 17 of the 19
cases (that is, with an accuracy of 89.5%, corresponding to a
weighted accuracy of 88.7%). Weighted accuracy is defined
as the average of the proportion of correctly predicted cases
within the set of positive cases and that of correctly predicted
negative cases in the dataset.
Numerous statistical and machine learning methods have
been successfully applied to the analysis of microarray data-
sets; these methods include cluster analysis (hierarchical clus-
tering [4-7], self-organizing maps [8-10], and two-way
clustering [11]), regression analysis [12], nearest neighbor-
hood methods [14], decision trees [14-17], artificial neural
networks [18,19], support vector machines [20-23], principal
component analysis [24-28], singular value decomposition
[29-32], and multidimensional scaling [33,34]. A pattern-
based recognition method has been developed using other
kinds of data for prediction of outcome in preclinical and clini-
cal trials of cancer patients [35,36].
The present study uses LAD, a combinatorics, optimization,
and logic based methodology for the analysis of data. Specific
features of the LAD approach include the exhaustive examina-
tion of the entire set of genes (without excluding those that
have low statistical correlations with the outcome, or those
that have low expression levels), focusing on the classification
power of combinations of genes (without confining attention
only to individual genes) and on the possibility of extracting
novel information on the role of genes and of combinations of
genes through the analysis of these exhaustive lists.
LAD has been shown to offer important insights into problems
ranging from oil exploration [2], labor productivity analysis [37]
and country creditworthiness evaluation [38], to medical appli-
cation (for example, risk evaluation among cardiac patients
[39,40]), polymer design for artificial bones [41], computer-
ized pulmonology [42], genomic-based diagnosis and progno-
sis of lymphoma [43], and proteomics-based ovarian cancer
diagnosis [44].
The present study uses LAD to analyze a breast cancer
genomic dataset [3]. Our goals in re-examining that dataset
are to evaluate the potential of LAD in developing a prognostic
system for breast cancer using genomic data; to derive addi-
tional information about the influence of certain genes and
combinations of genes; and to identify new classes of patients.
We present an introduction to LAD, and develop a new type
of classification model that can distinguish between patients
who will have a metastasis-free survival of 5 years from the oth-
ers. The structure of the paper is as follows. In the Materials
and method section we briefly present the concepts and meth-
odology of LAD, illustrating them on a small 'demonstration
model', which can distinguish between poor and good prog-
nosis based on the expression levels of six genes. In the
Results section we present an 'enhanced model' with
improved accuracy, involving 17 genes and having excellent
sensitivity and specificity both on the training and on the testAvailable online http://breast-cancer-research.com/content/8/4/R41
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sets. It is shown that this model distinguishes between posi-
tive and negative cases in the training set with a weighted
accuracy of 100%, and exhibits a weighted accuracy of
82.5% in cross-validation experiments. On the test set, the
model classifies correctly 18 out of 19 cases. Numerous other
findings concerning the influence of various genes, and differ-
ences discovered between the structures of the training and
the test sets are also presented in the Results section.
The presentation of the 'enhanced model' not only allows the
construction of a high-accuracy prognostic model, but it also
makes possible the derivation of interesting conclusions about
the dataset, about significant genes and combinations of
genes, and about new classes of patients, among other fac-
tors.
Materials and methods
LAD concepts
It can be expected that 'large' or 'small' values of the expres-
sion levels of certain genes can determine the poor or bad
prognosis of a breast cancer patient. In order to express such
relations in more precise terms, it is natural to replace terms
such as 'large' and 'small' with conditions of the type '... is more
than' or '... is less than' a certain value. It is therefore natural to
examine the role of well chosen cut points associated with the
expression levels of genes. For instance, the observation that
low intensity levels of gene Contig15031_RC are (more or
less) characteristic for a poor prognosis is imprecise; it can be
reformulated as the ultra-simplistic classification system, 'If the
intensity level of gene Contig15031_RC is at most 0.055 then
the patient has a poor prognosis'. The assumption of this rule
is valid for 25 positive and 11 negative cases in the training set
(that is, it has a sensitivity of 25/34 = 73.5% and a specificity
of 33/44 = 75%).
Combinations of such cut point based conditions naturally
extend this idea. For instance, the combined requirement of
satisfying simultaneously the three conditions 'The intensity
level of gene Contig15031_RC is at most 0.055' and 'The
intensity level of gene NM_004035 is at least -0.106' and 'The
intensity level of the gene NM_003239 is at most -0.014' is ful-
filled by 22 of the 34 positive cases in the dataset and by none
of the negative ones. Again, these three requirements could be
viewed as a classification system of poor prognosis cases,
having a sensitivity of 64.7% and a specificity of 100%.
Such ideas are at the foundation of LAD. The essence of LAD
is to detect patterns, or combinatorial biomarkers (that is, sim-
ple classifiers consisting of restrictions imposed on the values
of the expression levels of the intensities of a combination of
several genes); to generate patterns exhaustively and in an
algorithmically efficient way; to use the collection of patterns
as a prognostic system and thoroughly validate it; to extract
from this collection as much additional information as possible
about the role and nature of genes in the dataset (that is, to
detect promoters and blockers); and to study the common
characteristics of groups of patients that satisfy similar pat-
terns.
We describe below the basic concepts used in LAD, including
some of its computational aspects. In particular, we describe
more precisely the concepts of support sets, patterns, pan-
dects, and LAD-based classification systems, and we discuss
the validation techniques used.
Cut points and binarization
One of the underlying principles of LAD is to disregard the
exact values of a variable (for example, a gene), specifying for
each patient only whether the corresponding value of this var-
iable is sufficiently 'large' or 'small'. The implementation of this
principle requires the determination of several cutpoints c'j, c"j,
..., for intensity levels Ij of each gene j, such that the conditions
requiring that the expression levels of the gene's intensity are
low (or high) can be formalized as Ij ≤ c'j (Ij ≥ c"j), and so on.
LAD associates to each variable xj and each possible cutpoint
cj a binary variable yj that is equal to 1 whenever xj ≥ cj, and to
0 otherwise. In this way, a numerical variable (for example,
specifying the expression levels of the intensity of a gene j) is
transformed into a large number of binary variables. Because
Table 1
The six-gene support set of the demonstration model
Gene Index Van't Veer id GeneBank DAVID gene name
1 AF 018081 AF018081 Collagen, type XVIII, alpha 1
2 NM 003239 NM_003239 Transforming growth factor, beta 3
3 NM 004035 NM_004035 Acyl-Coenzyme A oxidase 1, palmitoyl
4 Contig26768_RC AI743607 Exostoses (multiple) 1
5 Contig15031_RC AI347425 Oligodendrocyte myelin glycoprotein
6 Contig27639_RC AW134837 Ectonucleoside triphosphate 
diphosphohydrolase 2Breast Cancer Research    Vol 8 No 4    Alexe et al.
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the size of the dataset (which has been very large from the
beginning) increases even further, this problem is handled by
carrying out a 'filtering' process, which retains only a 'support
set' consisting of a very small number of these variables.
Support sets
In order to distinguish between measurements of good and of
poor prognosis patients, only a tiny fraction of the information
contained in the (original or binarized) dataset is needed. In
particular, all of the information about the vast majority of the
genes in the dataset is redundant. Moreover, even for the
genes that are not redundant, only a few (usually only one) of
the corresponding binary variables are needed. A set of binary
variables that are sufficient to distinguish poor from good
prognosis cases will be called a support set. A support set is
called 'minimal' if none of its proper subsets is a support set;
clearly, not every minimal support set is of minimum size. It is
important to note that a dataset may admit hundreds or thou-
sands of minimal support sets. The reduction of a large dataset
to a substantially smaller one that includes only the variables in
the chosen support set allows a major simplification of the
problem, and has great importance for diagnosis and progno-
sis (although, in some cases, the presence of a limited number
of redundant variables may be acceptable in terms of ensuring
greater stability of results).
The problem of finding minimal support sets has been mod-
eled elsewhere [1,2,45] as a typical 'set-covering' problem,
and numerous methods are known in combinatorial optimiza-
tion for the solution of this problem. In our case, the excessive
dimensions of the associated set-covering problem (approxi-
mately 20,000 constraints involving between 2 and 3 million
0–1 variables) required the use of powerful heuristics to trim
down the size of the problem. In order to be able to handle the
large problems typical for genomic and proteomic datasets, a
general heuristic size-reduction procedure has been devel-
oped [46]. The essence of this method is to balance the con-
flicting criteria of minimizing size and maximizing discrimination
between positive and negative observations. In contrast to
many statistically based methods, the support set generation
procedures of LAD are guided by the collective strength of the
subsets of variables, without being necessarily restricted to
those variables that have the highest individual correlation
coefficients with the outcome.
The feature selection procedure [46] applied for the van 't
Veer dataset consists of two stages. In a first 'filtering' stage,
a relatively small subset of relevant features was identified on
the basis of several combinatorial, statistical, and information/
theoretical criteria (for example, separation measure, envelope
eccentricity, system entropy, signal to noise ratio). In the sec-
ond stage, the importance of variables selected in the first step
was evaluated based on the frequency of their participation in
the set of all maximal patterns (see below) and generated
using an efficient, total polynomial time algorithm [47], and a
large proportion of the low impact variables was eliminated.
This step was applied iteratively, until a Pareto-optimal support
set was arrived at, which balanced the conflicting criteria of
simplicity and accuracy; in the construction of the demonstra-
tion and enhanced models this support set consisted of only
6, respectively 17, of the 25,000 genes.
The high sensitivity and specificity of the prognostic system
built on these small sets of genes are to a large extent due to
the qualities of the underlying support set.
Logical patterns
A 'conjunction' is a set of conditions that require that the binary
variables appearing in a selected subset of the support set
take specific (0 or 1) values (that is, that the expression levels
of the corresponding genes should be below or above certain
cut points). The typical conjunctions appearing in most data
analysis studies fix the values of not more than two or three
binary variables. A conjunction is called a positive (or negative)
pattern if its set of conditions are satisfied simultaneously by
'sufficiently many' of the positive (or negative) cases, and by
'sufficiently few' of the negative (or positive) cases.
For example, in the van 't Veer breast cancer dataset, if 'suffi-
ciently many' is defined as 'at least 30%', then the three con-
ditions 'The intensity level of the gene Contig15031_RC is at
most 0.055' and 'The intensity level of the gene NM_004035
is at least -0.106' and 'The intensity level of the gene
NM_003239 is at most -0.014' are fulfilled by 22 of the 34
positive cases in the training set and by none of the negative
cases. Therefore, the simultaneous fulfillment of these three
conditions describes a positive pattern (to be denoted P1).
Similarly, the three conditions 'The intensity level of the
AF018081 is at most 0.071' and 'The intensity level of the
gene Contig26768_RC is at most 0.098' and 'The intensity
level of the gene Contig15031_RC is at least 0.0915' are ful-
filled by 15 of the 44 negative cases in the dataset and by
none of the positive cases. Therefore, the simultaneous fulfill-
ment of these three conditions describes a negative pattern
(to be denoted N1).
Two of the most important characteristics of a pattern are its
'degree' and its 'coverage'. The degree of a pattern is simply
the number of variables (genes) involved in its defining condi-
tions. In our example, both P1 and N1 have degree 3. A case
C is said to 'display' a pattern, or to be 'covered' by it, if the
corresponding intensity levels of the gene expressions satisfy
the defining conditions of that pattern. The prevalence of a
positive (or negative) pattern is simply the proportion of posi-
tive (or negative) cases covered by it. For example, the three
defining conditions of P1 are satisfied simultaneously by 22 of
the 34 positive cases (that is, the prevalence of P1 is 64.7%).
Similarly, N1 covers 15 of the 44 control cases (that is, its
prevalence is 34.1%). Patterns that cover only positive or only
negative cases are called 'pure' patterns. Clearly, both P1 andAvailable online http://breast-cancer-research.com/content/8/4/R41
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N1 are pure patterns. Usually, datasets that admit pure pat-
terns of low degrees and high prevalences allow the construc-
tion of reliable LAD diagnostic and prognostic systems.
Several combinatorial algorithms [47-50] are available for the
efficient generation of libraries of patterns. These pattern
extraction algorithms are intended to identify exhaustively the
collections of positive and negative patterns hidden in the
dataset, without any prior knowledge of the distribution of the
data domain.
As an indication of their efficiency, we note that the generation
of the 133,920 potential patterns examined for this study and
the selection of the 385 maximal pure patterns required a total
computer time of 5.1 s.
It should be noted that the concept of patterns resembles that
of rules, which appears in expert systems and in various deci-
sion tree-based methods. It should also be mentioned that the
number of rules in a dataset is exponentially large, and there-
fore the generation of every possible rule is not realistic.
Although most of the rule-based methods generate a relatively
small number of potentially significant rules, one of the major
characteristics of LAD is the systematic generation of an
extremely large collection of potentially significant rules, and in
a subsequent stage the 'filtering' of this collection in order to
retain only a reasonably sized collection that can jointly explain
the positive or negative nature of every case in the dataset.
This approach not only ensures that there is the possibility of
selecting those rules or patterns that, taken individually, carry
the greatest amount of information (for example, have low
degrees and high coverages); it also maximizes the collective
inference power of the selected family of patterns. In essence,
the pattern generation system of LAD consists of a systematic,
exhaustive combinatorial enumeration process, which is
guided by clear optimization criteria.
Pandects
The pandect (i.e. the collection of all of the positive and nega-
tive patterns corresponding to a dataset) is an important com-
ponent of LAD because it allows construction of diagnostic
and prognostic systems, analysis of the importance and role of
variables, and identification of new classes of observations,
among other factors. In view of the enormous number of pat-
terns corresponding to a dataset, the construction of the entire
pandect is not realistic. However, it has been seen in numer-
ous case studies that the knowledge of special subsets of the
pandect is sufficient for accurate analysis of datasets. The set
of all positive (or negative) patterns of degree at most d+ (or d-
) and prevalence at least p+ (or p-) is called the (d+, p+) positive
pandect (or the (d-, p-) negative pandect). The best pandect-
defining parameters d+, d-, p+, and p- for the analysis of a par-
ticular dataset are determined experimentally by carrying out a
series of k-fold cross-validation experiments. The computa-
tional complexity of generating the pandect depends mostly
on the values of d+ and d-. Because in most cases very small
values (usually not more than 2 or 3) of d+ and d- are sufficient
for the generation of an extremely useful pandect, this compo-
nent of LAD can be calculated in a very efficient way. The par-
ticular pandect used in the present study is defined by d+ = d-
= 3 and p+ = p- = 15%, and consists of 215 positive and 170
negative patterns. Although patterns can be viewed as tests
that are indicative of a good or bad prognosis, the 'pandect'
plays the role of a high powered prognostic battery of tests.
Clearly, the pandect is not a minimal system because it may
contain many redundant patterns, without which the system
can still remain accurate. As a matter of fact the pandect of the
van 't Veer dataset contains several minimal separating sub-
sets of patterns (called 'models'); two such models are dis-
cussed in this report: a 'demonstration model' consisting of
nine positive and seven negative patterns, and an 'enhanced
model' consisting of 20 positive and 20 negative patterns. It
should be added that the built-in redundancy of the large pan-
dect of 215 + 170 patterns can substantially increase [51] the
prognostic system's 'stability' or 'robustness' when it is
applied to new cases.
Pattern space
In the given dataset, each patient is described in terms of
approximately 25,000 attributes (genes) by specifying their
respective expression levels. Taking into account the fact that
LAD patterns can be viewed as logically synthesized attributes
that can be expected to reflect more closely the condition of a
patient than the original 'raw data', it is reasonable to assume
that a description of patients specifying exactly the set of pat-
terns by each individual should represent more precisely the
patient's condition. This pattern-based representation of the
observations can be achieved by associating to each patient
and to each pattern in the pandect an indicator variable that
shows whether the patient satisfies (indicator = 1) or does not
satisfy (indicator = 0) the conditions that define that pattern. In
this way, each patient is characterized by a sequence of 0–1
values of the indicator variables associated with the positive
and negative patterns in the pandect.
Calibration
The quality of the prognosis given by the pandect is a conse-
quence of the choice of several control parameters. The col-
lection of control parameters include the number of cutpoints
per gene, upper bounds on the size of support sets, pattern
degrees, and lower bounds on pattern prevalence. The control
parameters define uniquely the pandect. The best values of the
control parameters are determined iteratively by assigning
some values to them, constructing the associated pandect,
verifying the correctness of its predictions, reassigning the val-
ues, and continuing this sequence of steps until one arrives at
a pandect with highly accurate predictions. The verification
process is based on well known statistical cross-validation
techniques.Breast Cancer Research    Vol 8 No 4    Alexe et al.
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The most frequently used cross-validation techniques are the
leave-one-out (or jackknifing) method and of k-folding. All of
the cross-validation techniques are conducted within the train-
ing set (that is, they do not involve any observation in the test
set). In leave-one-out, one of the cases is taken as verification
set, the pandect is built on the remaining cases (the learning
set), and its prognosis is checked on the unique case in the
verification set, with this experiment being repeated for each
case in the training set. In k-folding, the training set is parti-
tioned randomly into k (for example, 2, 5, or 10) subsets; one
of these subsets is then selected as the verification set, the
pandect is constructed on the remainder of the training set
(viewed as the learning set), and the prognosis of the pandect
is checked on the verification set. This experiment is repeated
k times, for each of the k possible selections of the verification
set.
The entire calibration process is conducted only on the train-
ing set and it is intended to identify the best parameters to be
used in the construction of the LAD models, and not to validate
the LAD predictions (that process is described below).
Validation
Validation of the LAD results can be carried out in two ways.
First, the predictions of the pandect built on the training set
must be checked on the test set. This is the most frequently
used validation method. In order to increase the reliability of
the proposed pandect, an additional validation procedure can
be applied. In this second validation procedure, a new dataset
is created that consists of all of the observations in the original
training and test sets. The second validation consists of the
application of the usual cross-validation techniques (k-folding
Table 2
Demonstration LAD model consisting of nine positive and seven negative patterns on the support set of six genes
Patterns Definition of patterns Patterns' coverages 
(prevalences) on training set
AF018081 NM_003239 NM_004035 Contig26768_RC Contig15031_RC Contig27639_RC
Attr. 1 Attr. 2 Attr. 3 Attr. 4 Attr. 5 Attr. 6 Positive 
prevalence
Negative 
prevalence
P1 ≤-0.014 >-0.106 ≤0.055 22 (64.71%) 0
P2 >-0.232, ≤0.0575 >-0.106 >-0.2305 17 (50%) 0
P3 ≤-0.0945 ≤0.0915 >-0.1555 13 (38.24%) 0
P4 >-0.12 >-0.1555, ≤-0.014 ≤0.1145 12 (35.29%) 0
P5 >-0.12, ≤0.0055 ≤0.0575 ≤0.1485 11 (32.35%) 0
P6 >-0.2025 >-0.106, 
≤0.0455
>-0.0065, ≤0.055 11 (32.35%) 0
P7 >-0.08 >-0.0345 >-0.1555, 
≤0.1445
9 (26.47%) 0
P8 >0.071 >-0.106, 
≤0.0775
>-0.1555 9 (26.47%) 0
P9 >-0.319 >0.035 >-0.1555, 
≤0.1445
6 (17.65%) 0
N1 ≤0.071 ≤0.098 >0.0915 0 15 (34.09%)
N2 >0.1145 ≤0.037 0 15 (34.09%)
N3 ≤0.071 >0.0575 >-0.0635 0 14 (31.82%)
N4 ≤-0.106 0 13 (29.55%)
N5 >-0.014 ≤-0.1555 0 12 (27.27%)
N6 >-0.1335, ≤0.098 >0.055 ≤0.037 0 11 (25%)
N7 >-0.319 >0.035 >0.055, ≤0.1485 0 7 (15.91%)
LAD, logical analysis of data.Available online http://breast-cancer-research.com/content/8/4/R41
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and/or leave-one-out) to this augmented dataset, using the
parameters found at the calibration stage.
Illustration with a demonstration model
The LAD method was trained and calibrated on the same train-
ing set of 78 samples used by van't Veer and coworkers [3].
The prognosis results for LAD were validated on the same test
set of 19 samples used by van't Veer and coworkers. The sam-
ples in the test set were disregarded during the training proce-
dure.
Support set selection
The LAD method starts with a pre-processing procedure for
the selection of a significant support set of genes, on which
the proposed prognostic system will be constructed. Because
these systems are expected to have high accuracy, we
restricted our study only to those 13,387 genes whose log-
ratio measurements of fluorescence intensities are known for
every single patient (that is, we eliminated those genes that
include missing data). Part of our feature selection uses some
statistical measures, and for this purpose we normalize the
data by applying the following formula: x → (x - x_min)/(x_max
- x_min).
After removing variables based on these measures, the origi-
nal variables are reintroduced and a support set is determined.
We recall that a support set consists of a subset of variables
with the property that a model can build on them (not including
any variable outside the support set), which can distinguish
positive cases from negative ones.
In our dataset, from the set of 13,387 genes, using the method
presented by Alexe and coworkers [46], we have extracted
several support sets, including one consisting of six genes
(Table 1), on which we shall build a 'demonstration model'
(Table 2). Out of the six genes in the support set, one is
involved in cell growth and three are enzymes [52].
Because of the simplicity of the demonstration model, we use
it to illustrate the various concepts and procedures of LAD.
Binarization
We have used a simple binarization technique to replace the
expression level of each gene by several binary (0–1) varia-
bles, simply indicating whether the expression level does or
does not exceed certain thresholds. In order to achieve this,
we introduced several cut points into the range of fluores-
cence intensities of each gene, dividing it into three zones
(low, medium, and high). The cut points for each particular
gene were defined in such a way that the number of cases in
the training set having low, medium, or high expression levels
for that gene should be approximately equal.
Pattern and model generation
In order to ensure high reliability of the patterns used in the
demonstration model, we restricted our search to patterns of
prevalence at least 15% (for the enhanced model we required
the prevalences to be at least 20%). Furthermore, in order to
maximize the explanatory power of the patterns detected, we
restricted our search to patterns of degree 3 at most (that is,
involving at most three genes). In this way, using the support
set of six genes we have identified a pandect of 215 positive
and 170 negative patterns and extracted from it the demon-
stration model consisting of only nine positive and seven neg-
ative patterns, as shown in Table 2.
Each row in Table 2 describes a pattern. The first entry in the
row is the name of the pattern (for example, P1 in the first row
describes the first positive pattern). The next six entries
describe the defining conditions of that pattern (for example,
P1 is described by the three conditions 'Gene NM_003239 ≤
-0.014', 'Gene NM_004035 > -0.106', and
'Contig15031_RC ≤ 0.055'). The last two entries indicate the
positive and negative coverages (that is, the number of cases
satisfying the defining conditions of the pattern) and preva-
lences (that is, proportion of positive, or negative, cases satis-
fying the defining conditions) of the pattern on the training set.
For instance, P1 covers 22 of the 34 positive cases and none
of the negative cases in the training set; therefore, its positive
and negative prevalences on the training set are 64.7% and
0%, respectively.
Prognosis
The availability of the pandect makes it possible to classify
new (that is, not yet seen) observations as being positive or
negative. As a matter of fact, diagnosis and prognosis are per-
haps the most important applications of LAD to biomedical
problems. The most direct way to apply LAD to prognostic
problems is to examine which patterns are displayed by a new
case. If the case displays only positive patterns, then it is
assigned a poor prognosis. Similarly, if it displays only negative
patterns, then it is assigned a good prognosis. If the case does
not display any pattern, then no prognosis can be assigned to
it; it should be noted that this situation is extremely rare and did
not occur at all in the present study. Finally, if a case displays
both positive and negative patterns, then a simple weighting
procedure is applied to determine whether the positive or the
negative patterns are predominant. The weighting procedure
consists simply of comparing the proportion of the displayed
positive patterns in the set of all positive patterns contained in
the model (pandect), with the analogous proportion of nega-
tive patterns.
To illustrate the way in which a model can be used to predict
the positive (negative) nature of a 'new' patient, let us consider
one having the following values of his six attributes appearing
in the demonstration model: AF018081 = -0.029,
NM_003239 = -0.013, NM_004035 = -0.17,Breast Cancer Research    Vol 8 No 4    Alexe et al.
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Contig26768_RC = -0.033, Contig15031_RC = 0.132, and
Contig27639_RC = -0.16. This patient will satisfy one (P5) of
the nine positive patterns and five (N1, N2, N4, N5 and N6) of
the seven negative patterns appearing in the demonstration
model shown in Table 2. Therefore, the 'prognostic index' of
this patient will be (1/9) - (5/7) = -38/63; because the prog-
nostic index is negative, the model predicts this patient to be
in the 'negative' class.
Validation of the demonstration model
The demonstration model has been validated in several ways.
First, the direct application of the model to the training set of
78 observations resulted in 100% correct prediction of the
positive or negative nature of each case. The application of the
model to the test set of 19 cases resulted in a weighted accu-
racy of 81.6%, with 16 cases correctly predicted, one positive
case predicted as negative, and two negative cases predicted
as positive. Finally, 20 five-folding experiments on the training
set resulted in a weighted average of 75.3% correct predic-
tion, whereas 20 five-folding experiments on the combined
training and test set (containing 97 cases) resulted in a
weighted average of 76.2% accurate prediction.
Results
Prognostic system
We examined in the previous section a demonstration model,
built on the support set consisting of the six genes shown in
Table 1. Although the demonstration model provided high sim-
plicity and accuracy, its small size (number of genes and pat-
terns) makes it vulnerable to a lack of stability for small
variations in the level of gene expression. It is therefore reason-
able to build a more robust model using a larger support set
(for example, the enhanced support set of 17 genes, shown in
Table 3). It should be emphasized that this support set was
obtained independently of the support set of the demonstra-
tion model, not by the addition of supplementary genes to the
set, but by a bottom-up construction, which aimed at a solid
separation of positive and negative cases; the two support
sets are disjointed.
In this section we examine the enhanced model built on the 17
genes shown in Table 3. The functions of these genes,
obtained from the DAVID database [52], are summarized in
Table 3. Out of the 17 genes in the larger support set, one is
involved in cell growth, nine are involved in cellular metabolism
and one is involved in cellular adhesion [52].
Based on this 17-gene support set we constructed the
"enhanced" model shown in Table 4, which consists of 20
Table 3
The 17-gene support set of the enhanced model.
Gene Index Van't Veer id GeneBank DAVID_GENE_NAME
1 AB033007 AB033007 KIAA1181 protein
2 NM_001661 NM_001661 ADP-ribosylation factor 4-like
3 NM_001756 NM_001756 Serine (or cysteine) proteinase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 6
4 AF148505 AF148505 Aldehyde dehydrogenase 6 family, member A1
5 Contig42421_RC AI912791 F-box protein 16
6 NM_003748 NM_003748 Aldehyde dehydrogenase 4 family, member A1
7 NM_020974 NM_020974 Signal peptide, CUB domain, EGF-like 2
8 AL080059 AL080059 TSPY-like 5
9 AL110129 AL110129 Mitochondrial ribosomal protein S22
10 Contig15031_RC AI347425 Oligodendrocyte myelin glycoprotein
11 Contig65439 AI572600 Chromosome 20 open reading frame 178
12 Contig37063_RC AA579843 Poly (ADP-ribose) glycohydrolase
13 Contig41383_RC AA142876 Asparaginase like 1
14 AL049689 AL049689 Tenascin N
15 Contig63102_RC AI583960 Hypothetical protein FLJ11354
16 Contig55574_RC AA524093 F-box protein 41
17 Contig38451_RC AA497035 Not availableAvailable online http://breast-cancer-research.com/content/8/4/R41
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Table 4
'Enhanced LAD model' consisting of 20 positive and 20 negative patterns on support set of 17 genes
Patterns Definition of Patterns Patterns' 
coverages 
(prevalences) 
on training set
AB03
3007
NM_0
01661
NM_0
01756
AF148
505
Contig
4242
1_RC
NM_00
3748
NM_02
0974
AL0800
59
AL110
129
Contig
15031
_RC
Contig
65439
Contig
37063
_RC
Contig
41383_
RC
AL0496
89
Contig6
3102_R
C
Contig
55574
_RC
Contig3
8451_R
C
Attr. 1 Attr. 2 Attr. 3 Attr. 4 Attr. 5 Attr. 6 Attr. 7 Attr. 8 Attr. 9 Attr. 10 Attr. 11 Attr. 12 Attr. 13 Attr. 14 Attr. 15 Attr. 16 Attr. 17 Pos 
Prev
Neg 
Prev
P1 >-0.42 ≤0.09 ≤0.06 19 
(55.9%)
0
P2 ≤0.07 ≤-0.01 ≤0.07 18 
(52.9%)
0
P3 >-0.42 ≤0.06 ≤0.06 18 
(52.9%)
0
P4 ≤-0.01 ≤0.38 ≤0.07 18 
(52.9%)
0
P5 ≤0.07 ≤-0.45 ≤0.06 17 
(50.9%)
0
P6 ≤0.33 ≤-0.01 ≤-0.104 16 
(47.1%)
0
P7 ≤0.07 ≤-0.01 >-0.02 16 
(47.1%)
0
P8 ≤0.07 >-0.295 ≤0.033 16 
(47.1%)
0
P9 >-0.42 ≤0.06 ≤-0.001 14 
(41.2%)
0
P10 >-0.1 ≤-0.11 ≤-0.01 14 
(41.2%)
0
P11 ≤0.03 ≤-0.45 ≤0.19 13 
(38.2%)
0
P12 ≤0.07 >-0.295 >0.08 13 
(38.2%)
0
P13 ≤0.35 >-0.295 >0.08 13 
(38.2%)
0
P14 ≤0.3 ≤-0.001 >0.08 13 
(38.2%)
0
P15 ≤-0.03 >-0.16, 
≤0.07
12 
(35.3%)
0
P16 ≤0.35 >-0.96, 
≤-0.7
10 
(29.4%)
0
P17 >-0.22 ≤0.055 >-0.295 10 
(29.4%)
0
P18 >-0.22 >-0.48 >-0.1 10 
(29.4%)
0
P19 >-0.22 ≤0.32 ≤0.055 10 
(29.4%)
0
P20 >-0.22 >-0.1 >-0.27 10 
(29.4%)
0
N1 >0.09 >-0.005 0 15 
(34.1
%)
N2 ≤-0.295 >0.06 ≤-0.02 0 15 
(34.1
%)Breast Cancer Research    Vol 8 No 4    Alexe et al.
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N3 >-
0.11
≤0.14 ≤-0.02 0 15 
(34.1
%)
N4 >0.055 ≤-0.02 ≤1.88 0 14 
(31.8
%)
N5 >0.07 >-
0.001, 
≤0.17
0 14 
(31.8
%)
N6 >0.055 ≤-0.02 0 14 
(31.8
%)
N7 ≤-0.22 >0.06 >-0.005 0 14 
(31.8
%)
N8 >0.055 ≤-0.02 0 14 
(31.8
%)
N9 >0.09 >-0.005 >-0.083 0 14 
(31.8
%)
N10 >0.09 >-0.12, 
≤0.08
0 13 
(29.5
%)
N11 >-0.03 >0.06, 
≤0.14
0 13 
(29.5
%)
N12 >0.077 ≤0.35 >0.055 0 13 
(29.5
%)
N13 >0.077 ≤0.34 ≤-
0.0213
0 13 
(29.5
%)
N14 ≤-0.22 ≤0.18 >0.055 0 13 
(29.5
%)
N15 ≤0.21 >0.077 ≤-
0.0213
0 12 
(27.3
%)
N16 ≤-0.49 >-
0.1207
≤1.877 0 12 
(27.3
%)
N17 >0.06, 
≤0.14
≤-
0.0213
0 12 
(27.3
%)
N18 ≤0.22 >-0.12, 
≤-0.02
0 12 
(27.3
%)
N19 ≤0.16 ≤-0.42 >-
0.197
0 12 
(27.3
%)
N20 >-
0.204
>-
0.197
>0.13 0 11 
(25.0
%)
LAD, logical analysis of data
Table 4 (Continued)
'Enhanced LAD model' consisting of 20 positive and 20 negative patterns on support set of 17 genesAvailable online http://breast-cancer-research.com/content/8/4/R41
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positive and 20 negative patterns. It can be seen that the pat-
terns are very robust, having prevalences of up to almost 56%
in the positive case and above 34% in the negative case.
The classification provided by the enhanced model for the 34
patients with poor prognosis and the 44 patients with good
prognosis makes no errors in the training set (weighted accu-
racy = 100%). More significantly, on the 19-case test set
(which includes 12 positive and seven negative cases), the
system makes only one error and classifies correctly all of the
other cases; thus, the system's weighted accuracy is 92.9%.
The only error is a type 2 one, and it is due to the incorrect
classification of negative sample 119. The supplementary val-
idation tests based on an additional series of 20 five-folding
experiments on the combined dataset of 97 cases showed an
average weighted accuracy of 81.7%.
Significant biomarkers
Based on the frequency of inclusion of genes in the positive
patterns, it can be seen that Contig65439 (chromosome 20
open reading frame 178) plays a significant role in determining
a poor prognosis, because it appears in 10 of the 20 positive
patterns of the model. Similarly, Contig 55574_RC (F-box pro-
tein 41) plays a significant role in determining good prognosis,
because it appears in 11 of the 20 negative patterns of the
model.
Promoters and blockers
A gene with the property that an increase in the intensity level
of its expression (while the expression levels of the all other
genes remain unchanged) can sometimes worsen the progno-
sis, but can never improve it, will be called a 'promoter'. Simi-
larly, a gene with the property that a decrease in the intensity
level of its expression (while the expression levels of the all
other genes remain unchanged) can sometimes improve the
prognosis, but can never worsen it, will be called a 'blocker'.
Clearly, not every gene is a promoter or a blocker.
The model can identify promoters and blockers in the following
way. If every occurrence of a gene among the positive patterns
imposes a lower bound on its expression level (that is, in all
those patterns whose definition includes a condition concern-
ing that gene, the condition is of the form 'the expression level
of that gene is ≥ than a prescribed level'), while every occur-
rence of the same gene among the negative patterns imposes
an upper bound of its expression level (that is, in all those pat-
terns whose definition includes a condition concerning that
gene, the condition is of the form 'the expression level of that
gene is ≤ than a prescribed level'), then it can be concluded
that an increase in the expression level of that gene (assuming
that the expression levels of all the other genes remain
unchanged) may have as a result the activation of more posi-
tive patterns and/or the deactivation of some negative ones.
Therefore, an increase in the expression level of such a gene
can only increase the chances of metastasis formation. Such
a gene will be called a promoter.
Similarly, if every occurrence of a gene among the negative
patterns imposes an upper bound on its expression level
(namely, in all those patterns whose definition includes a con-
dition concerning that gene, the condition is of the form 'the
expression level of that gene is ≤ than a prescribed level'),
while every occurrence of the same gene among the positive
patterns imposes a lower bound of its expression level
(namely, in all those patterns whose definition includes a con-
dition concerning that gene, the condition is of the form 'the
expression level of that gene is ≥ than a prescribed level'), then
it can be concluded that an increase in the expression level of
that gene (assuming that the expression levels of all the other
genes remain unchanged) may have as a result the activation
of more negative patterns and/or the deactivation of some
positive ones. Therefore, an increase of the expression level of
such a gene can only decrease the chances of metastasis for-
mation. Such a gene will be called a blocker.
Using these definitions it is shown in Table 3 that genes
NM_001756, AL080059, and Contig55574_RC are promot-
ers, whereas genes NM_020974, Contig65439,
Contig15031_RC, Contig41383_RC, and Contig63102_RC
are blockers. The genes AF148505 and AL049689 also
exhibit blocker characteristics although to a somewhat lesser
extent; we view them as weak blockers.
Special classes of positive cases
In order to discover special classes, we conducted a series of
two-means clustering experiments of the positive observa-
tions, but they did not reveal the existence of any special sub-
groups of observations. However, using the pattern-based
representation of the positive cases (as described in the Mate-
rials and method subsection Pattern space), two-means clus-
tering revealed the existence of two very special classes of
patients. Despite the random element present in the nature of
the two-means clustering procedure, it transpired that in the
100 experiments we have carried out, the positive observa-
tions were repeatedly and consistently clustered into the same
two subgroups, which are denoted below by P+++ (consisting
of patient numbers 48, 50, 51, 59, 66, 68, and 69) and P+
(consisting of patient numbers 46, 52, 54, 55, 60, 62, 63, 73,
and 78) respectively; these subgroups have the following dis-
tinctive properties
Cohesion
The seven patients belonging to P+++ are assigned to a com-
mon cluster in 86% of the experiments, whereas the nine
patients belonging to P+ are assigned to another common
cluster in 98% of the experiments.Breast Cancer Research    Vol 8 No 4    Alexe et al.
Page 12 of 20
(page number not for citation purposes)
Predictability
In each validation experiment of the prognostic system by the
leave-one-out method, the prognosis of every single observa-
tion in P+++ was correct; the 100% accuracy of the prognostic
system on set P+++ is much higher than its 82.3% accuracy on
the set of positive cases not contained in P+++. On the other
hand, the accuracy of predictions for the patients in class P+
is only 55.6%.
Distinctive coverage by patterns
Each patient belonging to class P+++ satisfies 50–90% of the
positive patterns (68.5% on average), whereas each patient
belonging to P+ satisfies only 10–30% of the positive patterns
(20% on average).
Distinctive gene expression ranges
The smallest interval of the 17-dimensional real space contain-
ing P+++ does not contain any other positive or negative obser-
vation, whereas the one containing P+ also contains seven
negative observations (Table 5).
Statistical distinctions of clinical features
We shall say that feature 'f' is a 'contrastor' of subset S' of the
positive cases from the complementary set S" (consisting of
those positive cases that do not belong to S') if the following
two conditions hold: the average value of f in S' does not
belong to the 95% confidence interval of the values of f in S";
and the average value of f in S" does not belong to the 95%
confidence interval of the values of f in S'. With this definition,
it can be seen in Table 6 that the diameter and, to some extent,
the grade are contrastors, which distinguish P+++ from its
complement in the positive class. It can be also observed (see
Table 7) that class P+ has some distinguishing characteristics
(for example, the average PRp [progesterone receptor] of the
patients in this class is 55.6, whereas the average PRp of the
positive patients outside class P+ is 27.6, with the 95% confi-
dence interval ranging from 12.6 to 42.6).
Summary
It is clear that the classes P+ and P+++ are very special and that
all of the characteristics listed above indicate that it is most
likely that the patients belonging to class P+++ have a very
strong tendency toward developing metastases, whereas
those in P+ have a substantially reduced tendency.
Special classes of negative cases
Using the pattern-based representation of cases described in
the subsection Pattern space (above), we also carried out 100
two-means clustering experiments within the set of negative
observations. Despite of the random element present in the
nature of the two-means clustering procedure, it transpired
that, similar to the positive class, the negative class also con-
tains two disjointed (but not exhaustive) special subclasses.
These are denoted below by N--- (consisting of patient num-
bers 10, 18, 21, 23, 30, 32, 37, and 38) and N- (consisting of
patient numbers 2, 3, 4, 6, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20,
22, 24, 26, 27, 28, 33, 34, 36, 39, 40, 41, and 44), respec-
tively, and have the following distinctive properties.
Cohesion
The eight patients belonging to N--- are assigned to a common
cluster in 88% of the experiments, whereas the 26 patients
belonging to N- are assigned to a common cluster in 95% of
experiments.
Predictability
In each validation experiment of the prognostic system by the
leave-one-out method, the prognosis of every single observa-
tion in N--- was correct; the 100% accuracy of the prognostic
system on set N--- is much higher than its 77.8% accuracy on
the set of negative cases not contained in N---. On the other
hand, the accuracy of predictions for the patients in class N- is
only 73.1%.
Table 5
Description of the cases in the special positive class P+++
Gene 
Accessi
on 
Number
AB033
007
NM_00
1661
NM_00
1756
AF148
505
Contig4
2421_
RC
NM_00
3748
NM_02
0974
AL080
059
AL110
129
Contig1
5031_
RC
Contig6
5439
Contig3
7063_
RC
Contig4
1383_
RC
AL049
689
Contig6
3102_
RC
Contig5
5574_
RC
Contig3
8451_
RC
P+++ Lower 
bound
-0.13 -0.123 -0.193 -0.362 -0.281 -0.372 -1.125 -0.066 -0.078 -0.077 -0.268 -0.193 -0.095 -0.242 -0.453 -0.369 -0.119
Upper 
bound
0.108 0.044 0.381 0.116 -0.058 0.041 0.783 0.518 0.054 0.071 -0.009 0.116 0.07 0.115 0.048 0.525 0.268
Positive 
cases 
not in 
P+++
Lower 
bound
-0.174 -0.129 -0.708 -0.514 -0.601 -2 -1.337 -0.783 -2 -0.044 -0.263 -0.222 -0.567 -0.291 -0.345 -0.334 -0.147
Upper 
bound
0.363 0.329 0.638 0.386 0.671 0.487 0.942 0.776 0.418 0.418 0.211 0.494 0.393 0.431 0.444 0.256 2Available online http://breast-cancer-research.com/content/8/4/R41
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Distinctive coverage by patterns
Each patient belonging to the class N--- satisfies 50–70% of
the negative patterns (57.5% on average), whereas each
patient belonging to N- satisfies only 5–35% of the positive
patterns (20% on average).
Distinctive gene expression ranges
The smallest interval of the 17-dimensional real space contain-
ing N--- does not contain any other positive or negative obser-
vation, whereas the one containing N- also contains eight
positive observations (Table 8).
Statistical distinctions of clinical features
Similar to the positive case, we shall say that feature 'f' is a
'contrastor' of subset S' of the negative cases from the com-
plementary set S" (consisting of those negative cases that do
not belong to S') if the following two conditions hold: the aver-
age value of f in S' does not belong to the 95% confidence
interval of the values of f in S"; and the average value of f in S"
does not belong to the 95% confidence interval of the values
of f in S'. With this definition, it can be seen in Table 9 that
grade, estrogen receptor positive, and (to some extent) lym-
phocytic infiltrate are contrastors of N---. As far as class N-
goes, Table 10 shows the differences between the average
values of some of the parameters in class N- compared with
average values of the same parameters in the set of negative
cases outside N-.
Summary
It is clear that the classes N- and N--- are very special; all of the
characteristics listed above indicate that it is most likely that
patients belonging to class N--- are very strongly resistant to
development of metastases, whereas those in class N- have a
substantially milder resistance.
Discussion
Comparison of weighted accuracies
On the training set of 34 positive and 44 negative cases, the
model reported by van 't Veer and coworkers [3] model mis-
classifies 12 positive and three negative cases. The proposed
enhanced model classifies 100% of the cases in the training
set correctly. On the 19-case test set, the van 't Veer model
misclassifies two cases, whereas the enhanced model mis-
classifies one. We do not know whether the performance of
the model presented by van 't Veer and coworkers [3] has
been subjected to cross-validation (for example, by k-folding or
leave-one-out experiments), and therefore we can not conduct
a comparison with the cross-validation results of LAD, as
shown in Table 11.
Comparison of support sets
The study by van 't Veer and coworkers [3] considered two
support sets consisting of 70 and 231 selected genes,
whereas the enhanced model in the present study used a sup-
port set of 17 genes. Accuracy in distinguishing cases of poor
and good breast cancer prognosis provided by the subset of
70 genes selected by van 't Veer and coworkers was revali-
dated and confirmed by van de Vijver and colleagues [53] in a
different cohort of patients.
In order to assess further the performance of the reported sub-
sets of 231 and of 70 genes selected by van 't Veer and cow-
orkers [3], and of the support set of 17 genes selected for the
proposed enhanced LAD model, we applied LAD to each of
these three subsets of genes. We then constructed separate
predictive models on the training set and on the entire dataset
(consisting of 78 and 97 samples, respectively), and tested
their accuracy direct application both to the training set of 78
and to the entire dataset of 97 samples, and also by cross-val-
idation, consisting of 20 five-folding experiments. The results
are shown in Table 12.
Furthermore, we repeated the same type of experiments by
comparing the weighted accuracies of applying five frequently
used classification methods to the three support sets dis-
cussed above; these classification methods include artificial
neural networks, support vector machines, logistic regression,
nearest neighbours and decision trees, and are included in the
Table 7
Contrastors differentiating the positive cases in P+ from the 
positive cases outside P+
PRp
P+ Average 55.56
CI (95%) 26.50
84.61
Positive cases 
outside P+
Average 27.60
CI (95%) 12.59
42.61
CI, confidence interval; PRp, progesterone receptor.
Table 6
Contrastors differentiating the positive cases in P+++ from the 
positive cases outside P+++
Diameter (mm) Grade
P+++ Average 30.71 3.00
CI (95%) 25.31 3.00
36.12 3.00
Positive cases 
outside P+++
Average 22.67 2.81
CI (95%) 20.11 2.67
25.22 2.96
CI, confidence interval.Breast Cancer Research    Vol 8 No 4    Alexe et al.
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publicly available software WEKA [54]. The results are given
in Tables 13, 14, 15 and show that the average weighted
accuracy of the five methods applied to the support set of 17
genes compares favourably with the results obtained using the
two larger support sets of van 't Veer et al. and coworkers.
From these tables we can estimate the comparative average
weighted accuracies of the different predictive models con-
structed on the 17 genes of the enhanced model, and on the
70 and 231 genes selected by van't Veer and coworkers [3].
It can be seen that the 95% confidence intervals of weighted
accuracy estimated on the test set for the three predictive
models that use 17, 70 and 231 genes were 59.20–77.65,
42.15–58.91 and 72.67–76.79, respectively. Clearly, we can
conclude that the weighted accuracy in distinguishing patients
with good and poor breast cancer prognosis is best for the
model using 231 genes, is at a comparable (although slightly
lower) level for the model using 17 genes, and is at a substan-
tially lower level for the model using 70 genes.
Individual versus collective biomarkers
One of the important hypotheses raised by the LAD approach
concerns the role played in an accurate prognostic system by
those genes that have the greatest correlation with outcome.
In contrast to the conventional approach, LAD aims to go
beyond the straightforward goal of identifying genes with
important individual contributions to distinguishing between
breast cancer patients with good and poor prognosis, instead
focusing on those genes that – taken as a group – have the
greatest collective prognostic potential.
The breast cancer prognostic system developed in the present
study confirms the hypothesis that the most accurate prognos-
tic systems do not necessarily include only genes with strong
correlations with outcome. Indeed, the 70 biomarkers used in
the study by van 't Veer and coworkers [3] are extracted from
the pool of 231 genes that (taken individually) are most highly
correlated with the outcome. On the other hand, the 17-gene
support set selected by LAD includes several genes whose
correlation with the outcome in absolute value is very low. The
average absolute value of Pearson correlation with the out-
come of the 17 individual genes in the support set of the
enhanced LAD model is only 0.33. However, the average
absolute value correlation with the outcome of the 40 positive
and negative patterns (which can be viewed as collective
biomarkers) is higher, at 0.46.
It is interesting to note that the overlap between the set of 17
genes selected by LAD and the set of the 70 genes used in
the study by van't Veer and coworkers [3] consists of only four
genes (AL080059, NM_003748, NM_020974 and
Contig63102_RC). Also, the overlap between the set of 17
genes and the pool of 231 genes, from which the 70 biomar-
kers were extracted by van't Veer and coworkers, consists of
only eight genes (the four mentioned above and AB033007,
AF148505, Contig42421_RC, and Contig37063_RC).
The high accuracy of the LAD model is not due to the role of
the individual genes selected, but rather to the interactions
Table 8
Description of the cases in the special negative class N---
Gene 
Accessi
on 
Number
AB033
007
NM_00
1661
NM_00
1756
AF148
505
Contig
42421_
RC
NM_00
3748
NM_02
0974
AL080
059
AL110
129
Contig
15031_
RC
Contig
65439
Contig
37063_
RC
Contig
41383_
RC
AL049
689
Contig
63102_
RC
Contig
55574_
RC
Contig
38451_
RC
N--- Lower 
bound
0.041 -0.112 -0.65 0.007 -0.126 0.059 -0.976 0.05 0.05 0.085 -0.266 0.062 -0.251 0.039 -0.022 -0.255 0.02
Upper 
bound
0.21 0.228 0.166 0.453 0.386 0.675 -0.038 0.394 0.394 0.285 0.293 0.247 0.401 0.35 0.278 -0.024 0.303
Negative 
cases 
not in N---
Lower 
bound
-0.144 -0.106 -0.734 -0.294 -0.407 -1.253 -0.844 -0.214 -0.214 -0.115 -0.307 -0.179 -0.291 -0.21 -0.395 -0.343 -0.206
Upper 
bound
0.345 0.443 1.135 0.363 0.521 0.881 0.311 0.477 0.477 0.273 0.293 0.433 0.482 0.455 0.335 0.22 0.323
Table 9
Contrastors differentiating the negative cases in N--- from the 
negative cases outside N---
Grade ERp Lymphocytic 
infiltrate
N--- Average 1.75 78.75 0.00
CI (95%) 1.43 61.60 0.00
2.07 95.90 0.00
Positive cases 
outside N---
Average 2.42 57.22 0.14
CI (95%) 2.17 44.98 0.02
2.67 69.46 0.25
CI, confidence interval; ERp, estrogen receptor.Available online http://breast-cancer-research.com/content/8/4/R41
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among various genes in the 'collective biomarkers' repre-
sented by patterns. The concept of collective biomarkers is
crucial to the LAD approach.
Contrast between training and test sets
One of the most frequently used validation techniques in a
model learned on a training set is to apply it to a test set, and
to compare the accuracies of the model's predictions on the
two sets. It is usually assumed that characteristics of the train-
ing and test sets are very similar. The accuracy of predictions
obtained by LAD and other machine learning methodologies
on the test set is usually lower than that on the training set.
This phenomenon can be easily explained by the fact that any
such model learns the obvious and less obvious characteris-
tics of the training set, not all of which may be represented in
the test set. Surprisingly, in our analysis, the weighted accu-
racy on the test set (92.9%) turned out to be even higher than
that estimated by cross-validation on the training set (82.5%).
This suggests that a previously unrecognized, possibly sub-
stantial, difference existed between the training and the test
sets. In fact, we determined that this is the case.
Indeed, it can be seen that for the set of all observations in the
training set, with the exception of case number 70 (Sample
70), the intensity levels of gene NM_005839 (Ser/Arg-related
nuclear matrix protein [plenty of prolines 101-like]) are consist-
ently less than or equal to 0.19. On the other hand, on the test
set the intensity levels of the same gene are consistently
greater than 0.19. Therefore, it is clear that the intensity levels
of gene NM_005839 distinguish completely the observations
in the training set (with the exception of observation 70) from
all the observations in the test set.
The above finding is made even clearer by considering pat-
terns. It transpires that hundreds of patterns of degree 2 can
be found that completely separate the training set and the test
set, without any exceptions (not even for the observation 70
mentioned above).
The existence of pairs of genes that can distinguish between
the training and test sets is an extremely rare situation. The
existence of individual genes allowing such a distinction is
clearly even more surprising. Even in datasets in which the
training and test samples are collected in different laborato-
ries, the existence of such genes or pairs of genes is highly
unlikely. For instance, no such separation exists for the micro-
array dataset Leukemia AML-ALL studied by Golub and cow-
orkers [55].
As an additional distinguishing characteristic of the training
and test sets, let us consider the upper and the lower bounds
of each variable for the 19 test cases, as shown in Table 16. It
is clear that the measurements of none of the training set
cases fit into the ranges of the 17 variables in the table. Tech-
nically, this means that if we define the interval closure of a set
S of points as being the smallest interval [S] of the 17-dimen-
Table 10
Contrastors differentiating the negative cases in N- from the negative cases outside N-
Follow-up time 
(years)
Grade ERp PRp Lymphocytic 
infiltrate
N- Average 8.16 2.58 47.31 36.92 0.19
CI (95%) 7.28 2.31 32.62 23.19 0.04
9.04 2.85 62.00 50.65 0.35
Negative cases 
outside N-
Average 9.48 1.89 81.11 56.94 0.00
CI (95%) 8.20 1.58 71.23 40.61 0.00
10.76 2.20 90.99 73.28 0.00
CI, confidence interval; ERp, estrogen receptor; PRp, progesterone receptor.
Table 11
Comparison of weighted accuracies of the van 't Veer Classifier and the enhanced LAD model
Training set (78 cases) Test set (19 cases) Entire dataset (78 + 19 cases)
Direct classification (%) Cross-validation (%) Direct classification (%) Cross-validation (%)
Van 't Veer classifier [4] 83.6 Not reported 88.7 Not reported
Enhanced LAD model 100 82.52 92.86 81.74
LAD, logical analysis of data.Breast Cancer Research    Vol 8 No 4    Alexe et al.
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sional Euclidean space R17 spanned by the points in S, then
the interval [test set] does not contain any of the observations
included in the training set.
The observations presented above led us to the conclusion
that the training and the test sets have different characteris-
tics.
Individualized therapy
An important consequence of the identification of genes that
are promoters or blockers is the possibility of targeting thera-
pies in such a way that they should raise the expression of
some blockers and/or lower those of some promoters. An
even more attractive challenge is that of developing individual-
ized therapies, which target the particular blockers and pro-
moters present in the specific positive and negative patterns
'triggered' by the expression levels of an individual's genes.
Prognostic index
The results presented in the subsections Special classes of
positive cases and Special classes of negative cases (above)
indicate the existence of a possibly strong correlation between
the weighted accuracy of prognosis and the proportion of pat-
terns covering a case. Similarly to the index introduced by
Alexe and coworkers [40] for risk stratification among cardiac
patients, it is to be expected that a prognostic index for breast
cancer patients could also be developed.
Comparison with other studies
Various research groups have focused on finding molecular
signatures of cancer prognosis. Ramaswamy and coworkers
[56] analyzed the gene expression profiles of 12 metastatic
adenocarcinoma nodules of diverse origins (lung, breast, pros-
tate, colorectal, uterus, and ovary), and detected 17 gene sig-
natures associated with metastases. Eight out of the 17 genes
(SNRPF [small nuclear ribonucleoprotein F], EIF4EL3 [elon-
gation initiation factor 4E-like 3], HNRPAB [heterogeneous
nuclear ribonucleoprotein A/B], DHPS [deoxyhypusine syn-
thase],  PTTG1  [securin],  COL1A1  [type 1 collagen α1],
COL1A2  [type 1 collagen α2], and LMNB1  [lamin]) were
found to be upregulated in metastases, whereas the remaining
nine genes (ACTG2  [actin  γ2],  MYLK  [myosin light chain
Table 13
Weighted accuracies of various models constructed on the support set identified by LAD
Method Support set of 17 genes (LAD)
Training set (78 cases) Test set (19 cases) Entire dataset (78 + 19 cases)
Direct classification (%) Cross-validation (%) Direct classification (%) Cross-validation (%)
Artificial neural networks (1 hidden layer) 100.00 76.55 84.21 78.65
Support vector machines (linear kernel) 87.18 76.43 63.16 77.27
Logistic regression 94.87 76.87 73.68 77.95
Nearest neighbors 100.00 80.55 63.16 76.34
Decision trees (C4.5) 96.15 67.48 57.90 67.01
95% CI 91.03–100 71.33–79.82 59.20–77.65 71.25–79.64
CI, confidence interval; LAD, logical analysis of data.
Table 12
Comparison of weighted accuracies of the LAD models constructed on three different support sets
Support set Training set (78 cases) Test set (19 cases) Entire dataset (78 + 19 cases)
Direct classification 
(%)
Cross-validation 
(%)
Direct classification 
(%)
Direct classification (%)
231 genes (van't Veer [4]) 100.00 79.48 84.52 78.35
70 genes (van 't Veer [4]) 99.26 75.43 84.52 74.06
Proposed support set of 17 genes 100.00 82.52 92.86 81.74
LAD, logical analysis of data.Available online http://breast-cancer-research.com/content/8/4/R41
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kinase], MYH11 [myosin heavy chain 11], CNN1 [calponin 1],
HLA-DPB1 [MHC class II DPβ1], RUNX1 [runt-related tran-
scription factor 1], MT3 [metallothioein 3], NR4A1 [nuclear
hormone receptor TR3], and RBM5 [RNA binding motif 5])
were found to be downregulated. None of these 17 genes was
included among the poor prognosis signature in the study by
van 't Veer and coworkers [3], whereas only one of them
(COL1A1) was included in the support set of LAD.
Using cDNA gene expression profiling, van 't Veer and col-
leagues [57] showed that human primary breast cancer
tumors are similar to distant metastases of the same patient.
As concluded by Weigelt and coworkers [57], these findings
support the finding of van 't Veer and coworkers [3] that the
outcome of breast cancer can be predicted by the gene
expression signature of primary tumors. We wished to deter-
mine whether the genes in the support set identified by LAD
as being predictive of the breast cancer outcome would be
able to distinguish between paired primary breast tumors and
metastases. However, none of the genes in the LAD support
set of 17 genes were used in the 18,336 cDNA microarrays of
Weigelt and coworkers [57].
In a recent study, Dai and coworkers [58] showed that within
a group of patients with high estrogen receptor there is a
group of 50 mostly cell-cycle genes that are able to predict the
occurrence of metastases. The LAD support set of 17 genes
are disjointed with the set of 50 genes identified by Dai and
coworkers [58].
The fact that gene expression signature is predictive of human
breast cancer outcome was confirmed by various other inde-
pendent groups. For example, in an earlier study, Bertucci and
coworkers [59] confirmed that a 23-gene predictor set can
distinguish between breast cancer tumors associated with dif-
ferent survival rates. In that study, the cDNA profiles of tumor
samples from 55 women with poor prognosis breast cancer
treated with adjuvant anthracycline-based chemotherapy were
determined for 1000 candidate cancer genes. Those investi-
gators were able to distinguish three classes with significantly
different clinical outcome, as well as two estrogen receptor
positive tumor subgroups with different survival rates. The 23
genes identified in that study that predicted survival of chem-
otherapy-treated patients were disjointed from the support set
of 17 genes identified by LAD to predict metastases.
Sotiriou and coworkers [60] analyzed the cDNA expression
profiles of 99 breast cancer tumors and identified 485 genes
(out of the 7650 probe elements) associated with prognosis
in breast cancer. Only 11 of the 485 genes were included in
the subset of 231 genes identified by van 't Veer and cowork-
ers [3] as being correlated with breast cancer outcome. Sotir-
iou and coworkers showed these 11 genes to be able to
separate the breast cancer patients into two groups with dif-
ferent survival rates, thus confirming the findings of van 't Veer
and colleagues. Of the 17 genes in the LAD enhanced sup-
port set, none were found in the set of 485 genes [60].
Sorlie and colleagues [61] re-evaluated the performance of
the 231 genes of van 't Veer and coworkers in a comparative
study involving data from two other previous independent
groups (Norway/Stanford [62] and West and colleagues
[63]). Out of the 231 genes identified by van 't Veer and col-
leagues, 77 were found in the Norway/Stanford dataset.
Cross-validation experiments [61] showed that these 77
genes were able to discriminate between poor and good prog-
nosis of breast cancer tumors presented by van 't Veer and
colleagues [3] with 81% accuracy [3], thus confirming the
Table 14
Weighted accuracies of various models constructed on the support set of 70 genes identified by van 't Veer et al.
Method Support set of 70 genes (van 't Veer [33])
Training set (78 cases) Test set (19 cases) Entire dataset (78+19 cases)
Direct classification (%) Cross-validation (%) Direct classification (%) Cross-validation (%)
Artificial neural networks (1 hidden layer) 100.00 80.16 42.11 71.65
Support vector machines (linear kernel) 96.15 82.01 57.90 77.03
Logistic regression 100.00 73.52 47.37 73.79
Nearest neighbors 100.00 71.58 63.16 71.77
Decision trees (C4.5) 96.15 60.49 42.11 61.89
95% CI 96.61–100 66.09–81.01 42.15–58.91 66.27–76.18
The 70-gene set was reported by van 't Veer and coworkers elsewhere [4]. CI, confidence interval; LAD, logical analysis of data.Breast Cancer Research    Vol 8 No 4    Alexe et al.
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findings of van 't Veer. In addition, Sorlie and coworkers [61]
selected a subset of 534 intrinsic genes from the data in their
previous report [62], refining the results of van 't Veer and
coworkers [3] and West and colleagues [63], and showed the
existence of several subtypes of tumors. Sorlie's list of 534
intrinsic genes and LAD's support set of 17 genes contain
only one gene in common (ectonucleoside triphosphate
diphosphohydrolase 2).
Paik and coworkers [64] identified a set of 21 genes (includ-
ing 16 cancer-related and five reference genes) whose
expression could be used to predict the distant recurrence of
breast cancer in node-negative patients who were treated with
tamoxifen. The genes were selected from among 250 candi-
date genes discussed in the literature and which had high cor-
relation with the outcome of 447 patients in three independent
clinical studies. The set of genes identified by Paik and cow-
orkers and the genes identified by LAD were disjointed.
The fact that the vast majority of the 17 collective biomarkers
identified by LAD do not appear in the support sets selected
by univariate statistical methods clearly illustrates that combi-
natorial techniques can substantially supplement univariate
statistical methods in discovering sets of significant genes; the
set of clinically significant genes is far from being unique,
because many – even disjointed – significant sets of genes
have already been detected; and it is very likely that many as
yet undiscovered sets of significant genes exist.
Conclusion
Our LAD-based analysis of the data presented by van 't Veer
and coworkers [4] identified a new support set of 17 genes
that can fully distinguish between cases with poor prognosis
and those with good prognosis. The selection of the set of 17
genes took into account their collective interactive role in dis-
tinguishing cancer cases from controls (namely, we did not
simply select those genes that, taken individually, have partic-
ularly high expression levels or high correlations with the out-
come). We also established an explicit and highly accurate
classification model for breast cancer diagnosis, in which
every decision is explicit and transparent (that is, fully
described by the patterns of gene expression displayed by
each individual patient). Furthermore, we identified the relative
importance of each of the 17 genes, and identified those that
Table 16
Interval containing all the 19 cases in the test set and none of the 78 cases in the training set
Gene 
Accessi
on 
Number
AB033
007
NM_00
1661
NM_00
1756
AF148
505
Contig4
2421_
RC
NM_00
3748
NM_02
0974
AL080
059
AL110
129
Contig1
5031_
RC
Contig6
5439
Contig3
7063_
RC
Contig4
1383_
RC
AL049
689
Contig6
3102_
RC
Contig5
5574_
RC
Contig3
8451_
RC
Interval Lower 
bound
-0.212 -0.227 -0.541 -0.268 -0.301 -0.295 -1.085 -0.606 -0.144 -0.282 -0.325 -0.307 -0.106 -0.219 -0.347 -0.325 -0.245
Upper 
bound
0.187 0.017 0.29 0.22 0.394 0.309 0.557 0.401 0.241 0.062 0.303 0.272 0.117 0.304 0.331 0.576 0.183
Table 15
Weighted accuracies of various models constructed on the support set of 231 genes identified by van 't Veer and coworkers
Method Support set of 231 genes (van 't Veer [33])
Training set (78 cases) Test set (19 cases) Entire dataset (78 + 19 
cases)
Direct classification (%) Cross-validation (%) Direct classification (%) Cross-validation (%)
Artificial neural networks (1 
hidden layer)
100.00 72.24 73.68 73.96
Support vector machines 
(linear kernel)
100.00 72.79 73.68 74.88
Logistic regression 100.00 71.21 73.68 75.63
Nearest neighbors 100.00 72.94 78.94 77.15
Decision trees (C4.5) 97.44 60.70 73.68 66.64
95% CI 98.48–100.00 65.39–74.56 72.67–76.79 70.07–77.24
The 70-gene set was reported by van 't Veer and coworkers elsewhere [4]. CI, confidence interval; LAD, logical analysis of data.Available online http://breast-cancer-research.com/content/8/4/R41
Page 19 of 20
(page number not for citation purposes)
have a blocking or contributing influence on breast cancer. A
library of patterns (that is, logically synthesized combinations
of gene expression patterns that act as biomarkers for progno-
sis of breast cancer in large proportions of the population) was
established. Finally, we established a method for the automatic
generation of patterns of gene expressions that have a deter-
mining effect on classification. The classification power of the
patterns suggests the research hypothesis that they signify the
existence of an underlying biologic mechanism, which requires
elucidation.
This study suggests the applicability of the nonparametric
combinatorial method of LAD to genomic analysis of other
human cancers, as well as to the design of individualized ther-
apies based on the specific patterns of gene expressions for
each patient.
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